MANATT, PHELPS, AND PHILLIPS

MANATT, PHELPS, AND PHILLIPS filed a Q4 report for DENALI THERAPEUTICS on January 13, 2026, reporting $70,000 in lobbying income.

Lobbying for DENALI THERAPEUTICS · Biopharmaceutical Company

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 13, 2026

Income

$70,000

What the client paid this registrant for the period.

Client based in

California

Lobbying activity 1

Rare Pediatric Disease Priority Review Voucher (PRV) Program Reauthorization; Rare disease drug development

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.